| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2004 (ast)
- наукова стаття, опублікована у вересні 2004 (uk)
- مقالة علمية نشرت في سبتمبر 2004 (ar)
- scientific article published on September 2004 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| cites work
| |
| cites work
| - Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
- Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention
- Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
- Community-acquired pneumonia
- Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults
- Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate
- Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
- Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome
- A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections
- Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
- Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
- Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae
- The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate
- The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents
- Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent
- Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy
- Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae
- The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults
- Have we reached the point of no return? The hidden impact of antibacterial resistance in respiratory tract infection. Introduction
- Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia
|
| author name string
| |
| author name string
| - H Xie
- H Lode
- R Kozak
- H Kurz
- 600 Study Group
|
| rdfs:label
| - Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (en)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (nl)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (ast)
|
| skos:prefLabel
| - Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (en)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (nl)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (ast)
|
| name
| - Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (en)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (nl)
- Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)